@article{fab4096626f44f8d95be2b4cd650a2c6,
title = "Misfolded Transthyretin as a Novel Risk Factor for Heart Failure: A Rich History with Implications for Future Diagnosis and Treatment",
author = "Shah, {Sanjiv J.}",
note = "Funding Information: received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapies, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Funding Information: Cardiora, Corvia, CVRx, Cytokinetics, Eisai, GSK, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Sanofi, Shifamed, Tenax, and United Therapeutics. Dr Shah is supported by the National Heart, Blood, and Lung Institute (grants R01 HL107577, R01 HL127028, R01 HL140731, and R01 HL149423) and the American Heart Association (grant #16SFRN28780016).",
year = "2021",
month = mar,
doi = "10.1001/jamacardio.2020.5979",
language = "English (US)",
volume = "6",
pages = "255--257",
journal = "JAMA cardiology",
issn = "2380-6583",
publisher = "American Medical Association",
number = "3",
}